Lex Midweek Letter: arms out for boosters, thumbs up for mRNA

Covid-19 vaccine update

This article is an on-site version of The Lex Newsletter.sign up here Send the full newsletter directly to your inbox every Wednesday and Friday


Covid-19 vaccination drives are often referred to as race. On Tuesday it was compared to a camping trip. Anyone who has ever set up a small tent on the hillside knows that it makes sense to install a branch line before the storm, not during the storm, and they like the colorful metaphors of Britain. Professor Jonathan Vantam, a senior medical practitioner, said.

For over 50 and other qualified British Additional dose A dose of BioNTech / Pfizer jab or half the dose of Moderna vaccine will prevent the swell of weakened immunity. It’s also another vote of confidence in a new generation of shots that teach the body to use messenger RNA to make proteins that provoke an immune response.

A seven-booster study conducted at the University of Southampton found that mRNA jabs were the most tolerated and effective. Oxford / AstraZenecajab should only be used by people who cannot receive the mRNA vaccine for medical reasons.

Supplement Jab is not the only need. British Vaccine Minister Nadim Zahawi says patients can receive regular and annual Covid Jab at the same time they are vaccinated against the flu. Moderna co-founder Noubar Afeyan also talked about making the annual Covid booster a reality.

The need for regular booster immunization indicates that despite the remarkable success of the vaccine, it is unlikely to defeat the virus. The delta coronavirus mutant is about twice as infectious as the original strain originally detected in Wuhan. Herd immunity is out of reach because it cannot attack or infect enough people until it delays the transmission of the virus and disappears. Rather, Britain appears to be moving towards an “endemic equilibrium.” There, the case fluctuates at a relatively stable level. Immunity weakens over time, but boosters and waves of infection replenish it.

If confirmed, booster obligations will create a large and sustainable market for Covid vaccines. According to GlobalData, the annual Jab expands the Covid vaccine market across seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom and Japan from $ 13.6 billion in 2021 to $ 19.5 billion in 2026. Probably.

The profits of some companies will improve significantly. Pfizer, which shares profits with BioNTech in selling Covid shots, reports that the profit margin of the pre-tax Covid vaccine is in the “high 20% range.” Approval of rival vaccines may eventually lower prices, but so far they are rising. The EU paid € 19.50 per shot in the most recent transaction, up from € 15.50.According to one report, Britain Paid £ 1 billion The 35m dose ordered for the booster campaign next fall.

Vaccine costs are less controversial. They are inferior to the economic benefits of keeping the economy open. More controversial is the principle of providing booster jabs. Scientists such as Sara Gilbert, who developed the AstraZeneca jab, and the international author of Lancet’s recent treatise are not convinced. Pascal Soriot, AstraZeneca’s CEO, recently warned that rushing decisions could impose a potential “unnecessary burden” on the NHS.

Poorer countries have to wait longer — the more supplies are required by richer ones — increasing the death toll and the risk of new variants. The World Health Organization recently requested a moratorium of booster shots, at least until the end of the year, to allow all countries to vaccinate at least 40% of their population.

Pfizer boss Albert Bourla says the end of the jab shortage can be foreseen. According to life science analysis firm Airfinity, we predict that by the end of 2022, enough injections will be given to anyone who wants to be vaccinated. By the end of this year, developed countries have 1.1 billion surplus jabs. It’s a legacy of spreading their bets to prevent failure. The top of the league table is Canada with 8.8 doses per person, followed by the UK with 7 orders.

But Britain’s stockpile will not be as large as expected. France’s Valneva shares fell by more than a third on Monday after the British government terminated its 100 million vaccination contracts. The reason was not fully explained. British Health Minister Sajid Javid said it was clear that the vaccine was not approved for use in the United Kingdom.

Valneva insisted on pushing development. That’s not the only expectation that vaccine races will be marathons rather than sprints. More than 20 exams have been launched this year. According to Evaluate Vantage.. The first one out of the block has a big lead, but there may still be room for more candidates.

Enjoy the rest of the week,

Vanessa Holder
Rex lighter

If you want to receive regular updates every time you publish Lex, please add to. Your FT digest, You will receive an email alert immediately every time you publish. You can also see all the Lex columns from the web page.

Recommended newsletter for you

due diligence — The world’s top story of corporate finance.sign up here

City bulletin — Pre-market updates and commentary on Blythe Elder.sign up here

Lex Midweek Letter: arms out for boosters, thumbs up for mRNA Source link Lex Midweek Letter: arms out for boosters, thumbs up for mRNA

Related Articles

Back to top button